Results of Annual General Meeting and Share Consolidation
11 May 2023
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, is pleased to announce that at the Annual General Meeting of the Company held earlier today (the "Annual General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.
% of shares voted2
% of shares voted
1 Any proxy appointments which gave discretion to the Chairman have been included in the "for" total.
2 As a percentage of the aggregate of votes "for" plus votes "against".
3 An abstention is not counted towards the votes cast "for" or "against" a resolution.
The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Company's Shareholder Circular and Notice of Annual General Meeting (the "Circular") which was published and posted to Shareholders on 3 April 2023 and is available on the Company's website at https://investors.myhealthchecked.com/
At the Annual General Meeting, Shareholders approved, inter alia, the Share Consolidation, as detailed in the Circular.
The Share Consolidation consists of a consolidation of the ordinary shares of £0.001 each in the capital of the Company (the "Ordinary Shares"), such that every 15 Ordinary Shares will be consolidated into one new ordinary share of £0.015 nominal value each (the "Consolidated Ordinary Shares").
Following the Share Consolidation, the Company will have a single class of ordinary shares of £0.015 each in issue, being the Consolidated Ordinary Shares.
Admission of the Consolidated Ordinary Shares to trading on AIM
Application has been made to the London Stock Exchange plc for the admission to trading on AIM of the Consolidated Ordinary Shares, which is expected to become effective and dealings commence at 8.00 a.m. on or around 12 May 2023 (the "Consolidation Admission").
Total Voting Rights, ISIN, SEDOL and Par Value
The Consolidated Ordinary Shares have a new ISIN and SEDOL code, and the number of total voting rights in the Company's issued ordinary share capital will decrease as a result of the Share Consolidation.
Accordingly, upon the Consolidation Admission, the Company's issued share capital will consist of 52,005,932 Consolidated Ordinary Shares each with one voting right. The Company does not hold any ordinary shares in treasury. This figure may be used by Shareholders in the Company as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. In addition, the ISIN and SEDOL code of the Consolidated Ordinary Shares will be GB00BN7K5L93 and BN7K5L9, respectively.
Unless otherwise defined, capitalised terms used in this announcement have the same meanings as ascribed to them in the Circular sent to Shareholders dated 3 April 2023.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.
For further information contact:
Penny McCormick, Chief Executive Officer
via Walbrook PR
SPARK Advisory Partners Limited (NOMAD)
Tel: +44 (0)20 3368 3550
Dowgate Capital Limited (Broker)
Tel: +44 (0)20 3903 7715
David Poutney / Nicholas Chambers
Walbrook PR Ltd (Media & IR)
Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, and the sample collection kits enable the collection of blood, urine nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests will also be made available online and will be viable for over-the -counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.